Moderna (MRNA) ended the recent trading session at $26.68, demonstrating a -2.45% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 1.13%. At the same time, the Dow lost 1.79%, and the tech-heavy Nasdaq lost 1.3%. Shares of the biotechnology company witnessed a gain of 15.65% over the previous month, beating the performance of the Medical sector with its gain of 3.07%, and the S&P 500's gain of 3.55%.Market participants will be closely following the ...

Moderna, Inc. (NASDAQ:MRNA) Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 8:40 AM ET Company Participants Stéphane Bancel - CEO & Director Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Great. Good morning, everyone. Thank you so much for joining us. Really pleased to have Stéphane Bancel, CEO of Moderna, with us. Question-and-Answer Session Salveen Jaswal Richter Maybe to start here, Stéphane, in the context o ...

Moderna (MRNA) FY Conference June 11, 2025 08:40 AM ET Speaker0 So much for joining us. Really pleased to have Stephane Benzel, CEO of Moderna, with us. Maybe just start here, Stephane. You know, in the context of the current environment, both from a COVID demand and regulatory standpoint and the overall health care policy that we're seeing flow through from HHS and FDA and then there's the drug pricing dynamics. But just walk us through today where Moderna's business stands from a revenue and expenses stan ...

Moderna logo is seen in Warsaw, Poland on April 9, 2025. (Photo by Jakub Porzycki/NurPhoto via Getty ... More Images)NurPhoto via Getty ImagesModerna’s stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the European Union renegotiated its vaccine supply agreement with Pfizer and BioNTech. This information, combined with the company’s disappointing outlook, had a significant effect ...

Moderna, Inc. (NASDAQ:MRNA) Jefferies Global Healthcare Conference Call June 5, 2025 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Jonathan Yee - Jefferies LLC, Research Division Michael Jonathan Yee Hi, everyone. Thank you. Good morning, and thank you for joining us on our next discussion here at the Jefferies Healthcare Conference. I have the pleasure of having the President of Moderna. Stephen Hoge up here with us. Obviously, quite timely, a lot's on with ...

Moderna (MRNA) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Everyone, thank you. Good morning, and thank you for joining us on our next discussion here at the Jefferies Healthcare Conference. I have the pleasure of having the President of Moderna, Stephen Hoag, up here with us. Obviously, timely. A lot's going on in the world, both from a regulatory administrative standpoint. We had Marty Makary here yesterday. Obviously, a lot going on with your commercial business, the pipeline, all of that. So I lo ...

Key Takeaways Moderna received FDA approval for mNexspike, its next-gen COVID-19 vaccine with limited use criteria. Vaccine is cleared for older adults and high-risk individuals aged 12-64, not the broader group MRNA wanted. The vaccine offers a better shelf life and matched or outperformed Spikevax in late-stage trial data.Moderna (MRNA) announced the FDA approval for mRNA-1283, its next-generation refrigerator-stable COVID-19 vaccine, though for a label narrower than initially targeted. The vaccine will ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth?Moderna (NASDAQ: MRNA ) shares are down over 35% year-to-date, over 80% on a one-year basis, and since reaching their pandemic era high of over $450 per share, they are down 94%.The group is for both novice and expe ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Moderna, Inc. (NASDAQ:MRNA) Bernstein 41st Annual Strategic Decisions Conference Call May 29, 2025 10:00 AM ET Company Participants Stephane Bancel - CEO & Director Conference Call Participants Courtney Breen - Bernstein Courtney Breen So I am thrilled to be here today with Stephane Bancel from Moderna. My name is Courtney Breen. I am the U.S. Biopharma Analyst here at Bernstein. Before we dive into the Q&A, I will give Stephane the opportunity to give us some context to where Moderna is at, and then we'll ...